Key result
Cisplatin-based chemotherapy in testicular cancer survivors increased the risk of coronary artery disease compared to the general population (O/E ratio 7.1; 95% CI 1.9-18.3).
Why the study?
Does cisplatin-containing chemotherapy increase the risk of cardiovascular morbidity in long-term survivors of metastatic testicular cancer?
Cohort (n=127)
Does cisplatin-containing chemotherapy increase the risk of cardiovascular morbidity in long-term survivors of metastatic testicular cancer?
Effect estimate: O/E ratio 7.1 (95% CI 1.9-18.3)
Long-term survivors of metastatic testicular cancer treated with cisplatin-based chemotherapy have a significantly increased risk of premature coronary artery disease and an unfavorable cardiovascular risk profile.
No takes yet. Share an insight, caveat, or question.
May warrant CAD surveillance in survivors; leaves open prospective validation of mitigation strategies.
Meinardi et al. (2000) conducted a cohort in Metastatic Testicular Cancer (n=127). Cisplatin-containing chemotherapy vs. Orchidectomy only / general male population was evaluated on Major cardiac events and coronary artery disease (O/E ratio 7.1, 95% CI 1.9-18.3). Cisplatin-based chemotherapy in testicular cancer survivors increased the risk of coronary artery disease compared to the general population (O/E ratio 7.1; 95% CI 1.9-18.3).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: